The nomogram for the prediction of overall survival after surgery in patients in early-stage NSCLC based on SEER database and external validation cohort.

Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-

Carcinoma, Non-Small-Cell Lung*/surgery ; Lung Neoplasms*/surgery ; Adenocarcinoma*/surgery; Humans ; Male ; Nomograms ; Area Under Curve ; SEER Program ; Prognosis

Background & Aims: Currently, there is a lack of effective tools for predicting the prognostic outcome of early-stage lung cancer after surgery. We aim to create a nomogram model to help clinicians assess the risk of postoperative recurrence or metastasis.
Materials and Methods: This work obtained 16,459 NSCLC patients based on SEER database from 2010 to 2015. In addition, we also enrolled 385 NSCLC patients (2017/01-2019/06) into external validation cohort at Tianjin Medical University General Hospital. Univariable as well as multivariable Cox regression was carried out for identifying factors independently predicting OS. In addition, we built a nomogram by incorporating the above prognostic factors for the prediction of OS.
Results: Tumor size was positively correlated with the risk of poor differentiation. Advanced age, male and adenocarcinoma patients were factors independently predicting poor prognosis. The risk of white race is higher, followed by Black race, Asians and Indians, which is consistent with previous study. Chemotherapy is negatively related to prognostic outcome in patients of Stage IA NSCLC and positively related to that in those of Stage IB NSCLC. Lymph node dissection can reduce the postoperative mortality of patients. AUCs of the nomograms for 1, 2, and 3-year OS was 0.705, 0.712, and 0.714 for training cohort, while those were 0.684, 0.688, and 0.688 for validation cohort.
Conclusions: The nomogram could be used as a tool to predict the postoperative prognosis of patients with Stage I non-small cell lung cancer.
(© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Lancet Oncol. 2015 Apr;16(4):e173-80. (PMID: 25846097)
Chest. 2013 Jun;143(6):1626-1634. (PMID: 23348916)
N Engl J Med. 2023 Feb 9;388(6):489-498. (PMID: 36780674)
Thorax. 2010 Mar;65(3):241-5. (PMID: 20335294)
J Thorac Dis. 2022 Nov;14(11):4285-4296. (PMID: 36524081)
Cancer Med. 2024 Jan;13(1):e6751. (PMID: 38148585)
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):255-64. (PMID: 25417239)
Cochrane Database Syst Rev. 2016 Oct 11;10:CD002142. (PMID: 27727451)
Ann Transl Med. 2021 May;9(9):751. (PMID: 34268364)
J Natl Compr Canc Netw. 2021 Mar 02;19(3):254-266. (PMID: 33668021)
Chest. 2017 Sep;152(3):587-597. (PMID: 28450031)
J Healthc Eng. 2022 Dec 10;2022:5698582. (PMID: 36536690)
Transl Lung Cancer Res. 2021 Apr;10(4):1761-1772. (PMID: 34012791)
Expert Rev Anticancer Ther. 2018 Jan;18(1):63-70. (PMID: 29168933)
J Thorac Dis. 2020 Jun;12(6):3357-3362. (PMID: 32642260)
Sci Rep. 2022 Oct 1;12(1):16466. (PMID: 36183006)
Chest. 2005 Sep;128(3):1545-50. (PMID: 16162756)
Ann Surg Oncol. 2021 Jul;28(7):3941-3950. (PMID: 33249521)
Ann Thorac Surg. 2015 Sep;100(3):910-6. (PMID: 26165483)
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002142. (PMID: 15846628)
Ann Thorac Surg. 2022 Sep;114(3):989-997. (PMID: 34487710)
Nat Rev Cancer. 2014 Aug;14(8):535-46. (PMID: 25056707)
Thorax. 2009 Mar;64(3):192-6. (PMID: 19252018)
BMC Cancer. 2021 May 8;21(1):524. (PMID: 33964898)
Radiographics. 2018 Mar-Apr;38(2):374-391. (PMID: 29528831)
Lancet Respir Med. 2018 Dec;6(12):915-924. (PMID: 30442588)
BMC Cancer. 2020 Feb 24;20(1):150. (PMID: 32093621)
Front Oncol. 2022 Aug 15;12:916498. (PMID: 36033482)
Int J Gen Med. 2022 Sep 14;15:7287-7298. (PMID: 36133910)
J Clin Oncol. 2015 Sep 10;33(26):2877-84. (PMID: 26261257)
Transl Lung Cancer Res. 2022 Jul;11(7):1279-1291. (PMID: 35958321)
Eur J Surg Oncol. 2007 Aug;33(6):763-8. (PMID: 17306497)
BMC Cancer. 2020 Jul 17;20(1):666. (PMID: 32680464)
Front Med (Lausanne). 2022 Dec 21;9:972879. (PMID: 36619647)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Lung Cancer. 2015 Aug;89(2):121-32. (PMID: 26033208)
Ann Surg Oncol. 2016 Dec;23(Suppl 5):1005-1011. (PMID: 27531307)
Eur J Cardiothorac Surg. 2016 Jun;49(6):1624-31. (PMID: 26792922)
Ann Thorac Surg. 2012 May;93(5):1614-9; discussion 1619-20. (PMID: 22440365)

21JCYBJC01770 Diversified Input Project of Tianjin National Natural Science Foundation; 82172776 The National Natural Science Foundation of China; TJYXZDXK-061B Tianjin Key Medical Discipline (Specialty) Construction Project; 19ZXDBSY00060 Tianjin Municipal Science and Technology Program

Keywords: nomogram; non-small cell lung cancer; prognostic factor; the Surveillance, Epidemiology, and End Results Program (SEER)

Date Created: 20231227 Date Completed: 20240306 Latest Revision: 20241023

20241023

PMC10807635

10.1002/cam4.6751

38148585